1887

Abstract

At present, infections with bovine viral diarrhea virus (BVDV) type 2 occur nearly as frequently as those with BVDV type 1, so development of vaccines that protect cattle from both type 1 and type 2 BVDV has become critical. In this study, we compared various DNA prime–protein boost vaccination strategies to protect cattle from challenge with BVDV-2 using the major protective antigen of BVDV, glycoprotein E2. Calves were immunized with a plasmid encoding either type 1 E2 (E2.1) or type 2 E2 (E2.2) or with both plasmids (E2.1+E2.2). This was followed by a heterologous boost with E2.1, E2.2 or E2.1 and E2.2 protein formulated with Emulsigen and a CpG oligodeoxynucleotide. Subsequently, the calves were challenged with BVDV-2 strain 1373. All vaccinated calves developed both humoral and cell-mediated immune responses, including virus-neutralizing antibodies and IFN--secreting cells in the peripheral blood. Depletion studies showed that CD4 T cells were responsible for IFN- production. Furthermore, the calves vaccinated with either the E2.2 or the E2.1+E2.2 vaccines were very well protected from challenge with BVDV-2, having little leukopenia and showing no weight loss or temperature response. In addition, the animals vaccinated with the E2.1 vaccine were partially protected, so there was a certain level of cross-protection. These data demonstrate that a vaccination strategy consisting of priming with E2.2 or E2.1+E2.2 DNA and boosting with E2.2 or E2.1+E2.2 protein fully protects cattle from BVDV-2 challenge.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83251-0
2008-02-01
2020-09-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/2/453.html?itemId=/content/journal/jgv/10.1099/vir.0.83251-0&mimeType=html&fmt=ahah

References

  1. Anson D. S. 2004; The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2:9 [CrossRef]
    [Google Scholar]
  2. Baker J. C. 1995; The clinical manifestations of bovine viral diarrhea infection. Vet Clin North Am Food Anim Pract 11:425–445
    [Google Scholar]
  3. Barnett S. W., Rajasekar S., Legg H., Doe B., Fuller D. H., Haynes J. R., Walker C. M., Steimer K. S. 1997; Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15:869–873 [CrossRef]
    [Google Scholar]
  4. Bolin S. R., Ridpath J. F. 1992; Differences in virulence between two noncytopathic bovine viral diarrhea viruses in calves. Am J Vet Res 53:2157–2163
    [Google Scholar]
  5. Bolin S. R., Ridpath J. F. 1998; Prevalence of bovine viral diarrhea virus genotypes and antibody against those viral genotypes in fetal bovine serum. J Vet Diagn Invest 10:135–139 [CrossRef]
    [Google Scholar]
  6. Braun R., Babiuk L. A., van Drunen Littel-van den Hurk S. 1998; Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J Gen Virol 79:2965–2970
    [Google Scholar]
  7. Brownlie J., Clarke M. C., Hooper L. B., Bell G. D. 1995; Protection of the bovine fetus from bovine viral diarrhoea virus by means of a new inactivated vaccine. Vet Rec 137:58–62 [CrossRef]
    [Google Scholar]
  8. Canal C. W., Strasser M., Hertig C., Masuda A., Peterhans E. 1998; Detection of antibodies to bovine viral diarrhoea virus (BVDV) and characterization of genomes of BVDV from Brazil. Vet Microbiol 63:85–97 [CrossRef]
    [Google Scholar]
  9. Cardoso A. I., Sixt N., Vallier A., Fayolle J., Buckland R., Wild T. F. 1998; Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the coimmunized antigen. J Virol 72:2516–2518
    [Google Scholar]
  10. Collett M. S., Larson R., Belzer S. K., Retzel E. 1988; Proteins encoded by bovine viral diarrhea virus: the genomic organization of a pestivirus. Virology 165:200–208 [CrossRef]
    [Google Scholar]
  11. Collett M. S., Wiskerchen M., Welniak E., Belzer S. K. 1991; Bovine viral diarrhea virus genomic organization. Arch Virol Suppl 3:19–27
    [Google Scholar]
  12. Couvreur B., Letellier C., Collard A., Quenon P., Dehan P., Hamers C., Pastoret P. P., Kerkhofs P. 2002; Genetic and antigenic variability in bovine viral diarrhea virus (BVDV) isolates from Belgium. Virus Res 85:17–28 [CrossRef]
    [Google Scholar]
  13. Dean H. J., Leyh R. 1999; Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge. Vaccine 17:1117–1124 [CrossRef]
    [Google Scholar]
  14. Dunachie S. J., Walther M., Vuola J. M., Webster D. P., Keating S. M., Berthoud T., Andrews L., Bejon P., Poulton I. other authors 2006; A clinical trial of prime–boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24:2850–2859 [CrossRef]
    [Google Scholar]
  15. Ellis J., West K., Cortese V., Konoby C., Weigel D. 2001; Effect of maternal antibodies on induction and persistence of vaccine-induced immune responses against bovine viral diarrhea virus type II in young calves. J Am Vet Med Assoc 219:351–356 [CrossRef]
    [Google Scholar]
  16. Ellsworth M. A., Fairbanks K. K., Behan S., Jackson J. A., Goodyear M., Oien N. L., Meinert T. R., Leyh R. D. 2006; Fetal protection following exposure to calves persistently infected with bovine viral diarrhea virus type 2 sixteen months after primary vaccination of the dams. Vet Ther 7:295–304
    [Google Scholar]
  17. Evermann J. F., Ridpath J. F. 2002; Clinical and epidemiologic observations of bovine viral diarrhea virus in the northwestern United States. Vet Microbiol 89:129–139 [CrossRef]
    [Google Scholar]
  18. Fairbanks K. K., Rinehart C. L., Ohnesorge W. C., Loughin M. M., Chase C. C. 2004; Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine. J Am Vet Med Assoc 225:1898–1904 [CrossRef]
    [Google Scholar]
  19. Ficken M. D., Ellsworth M. A., Tucker C. M. 2006a; Evaluation of the efficacy of a modified-live combination vaccine against bovine viral diarrhea virus types 1 and 2 challenge exposures in a one-year duration-of-immunity fetal protection study. Vet Ther 7:283–294
    [Google Scholar]
  20. Ficken M. D., Ellsworth M. A., Tucker C. M., Cortese V. S. 2006b; Effects of modified-live bovine viral diarrhea virus vaccines containing either type 1 or types 1 and 2 BVDV on heifers and their offspring after challenge with noncytopathic type 2 BVDV during gestation. J Am Vet Med Assoc 228:1559–1564 [CrossRef]
    [Google Scholar]
  21. Fulton R. W., Burge L. J. 2000; Bovine viral diarrhea virus types 1 and 2 antibody response in calves receiving modified live virus or inactivated vaccines. Vaccine 19:264–274 [CrossRef]
    [Google Scholar]
  22. Fulton R. W., Johnson B. J., Briggs R. E., Ridpath J. F., Saliki J. T., Confer A. W., Burge L. J., Step D. L., Walker D. A., Payton M. E. 2006; Challenge with bovine viral diarrhea virus by exposure to persistently infected calves: protection by vaccination and negative results of antigen testing in nonvaccinated acutely infected calves. Can J Vet Res 70:121–127
    [Google Scholar]
  23. Galloway D., Liner A., Legutki J., Mateczun A., Barnewall R., Estep J. 2004; Genetic immunization against anthrax. Vaccine 22:1604–1608 [CrossRef]
    [Google Scholar]
  24. Hamers C., Couvreur B., Dehan P., Letellier C., Fischer L., Brun A. J., Lewalle P., Michaux C., Pastoret P. P., Kerkhofs P. 2003; Assessment of the clinical and virological protection provided by a commercial inactivated bovine viral diarrhoea virus genotype 1 vaccine against a BVDV genotype 2 challenge. Vet Rec 153:236–240 [CrossRef]
    [Google Scholar]
  25. Houe H. 1995; Epidemiology of bovine viral diarrhea virus. Vet Clin North Am Food Anim Pract 11:521–547
    [Google Scholar]
  26. Kim I. J., Hyun B. H., Shin J. H., Lee K. K., Lee K. W., Cho K. O., Kang M. I. 2006; Identification of bovine viral diarrhea virus type 2 in Korean native goat ( Capra hircus ). Virus Res 121:103–106 [CrossRef]
    [Google Scholar]
  27. Kong W. P., Huang Y., Yang Z. Y., Chakrabarti B. K., Moodie Z., Nabel G. J. 2003; Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77:12764–12772 [CrossRef]
    [Google Scholar]
  28. Konishi E., Kosugi S., Imoto J. 2006; Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24:2200–2207 [CrossRef]
    [Google Scholar]
  29. Kovacs F., Magyar T., Rinehart C., Elbers K., Schlesinger K., Ohnesorge W. C. 2003; The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection. Vet Microbiol 96:117–131 [CrossRef]
    [Google Scholar]
  30. Li Z., Zhang H., Fan X., Zhang Y., Huang J., Liu Q., Tjelle T. E., Mathiesen I., Kjeken R., Xiong S. 2006; DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine 24:4565–4568 [CrossRef]
    [Google Scholar]
  31. Liang R., van den Hurk J. V., Zheng C., Yu H., Pontarollo R. A., Babiuk L. A., van Drunen Littel-van den Hurk S. 2005; Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine 23:5252–5262 [CrossRef]
    [Google Scholar]
  32. Liang R., van den Hurk J. V., Babiuk L. A., van Drunen Littel-van den Hurk S. 2006; Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from bovine viral diarrhea virus in cattle. J Gen Virol 87:2971–2982 [CrossRef]
    [Google Scholar]
  33. Lu S. 2006; Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 28:255–265 [CrossRef]
    [Google Scholar]
  34. Martin J. E., Sullivan N. J., Enama M. E., Gordon I. J., Roederer M., Koup R. A., Bailer R. T., Chakrabarti B. K., Bailey M. A. other authors 2006; A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13:1267–1277 [CrossRef]
    [Google Scholar]
  35. McConkey S. J., Reece W. H., Moorthy V. S., Webster D., Dunachie S., Butcher G., Vuola J. M., Blanchard T. J., Gothard P. other authors 2003; Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9:729–735 [CrossRef]
    [Google Scholar]
  36. Moore Q. C., Bosarge J. R., Quin L. R., McDaniel L. S. 2006; Enhanced protective immunity against pneumococcal infection with PspA DNA and protein. Vaccine 24:5755–5761 [CrossRef]
    [Google Scholar]
  37. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E. G., Beattie T., Chen Y. H., Dorrell L. other authors 2004; A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85:911–919 [CrossRef]
    [Google Scholar]
  38. Nakamura Y., Gojobori T., Ikemura T. 2000; Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res 28:292 [CrossRef]
    [Google Scholar]
  39. O'Hagan D. T., Singh M., Ulmer J. B. 2006; Microparticle-based technologies for vaccines. Methods 40:10–19 [CrossRef]
    [Google Scholar]
  40. Pal R., Kalyanaraman V. S., Nair B. C., Whitney S., Keen T., Hocker L., Hudacik L., Rose N., Mboudjeka I. other authors 2006; Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348:341–353 [CrossRef]
    [Google Scholar]
  41. Pellerin C., van den Hurk J., Lecomte J., Tussen P. 1994; Identification of a new group of bovine viral diarrhea virus strains associated with severe outbreaks and high mortalities. Virology 203:260–268 [CrossRef]
    [Google Scholar]
  42. Pratelli A., Martella V., Cirone F., Buonavoglia D., Elia G., Tempesta M., Buonavoglia C. 2001; Genomic characterization of pestiviruses isolated from lambs and kids in southern Italy. J Virol Methods 94:81–85 [CrossRef]
    [Google Scholar]
  43. Raggo C., Habermehl M., Babiuk L. A., Griebel P. 2000; The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon- γ . J Gen Virol 81:2665–2673
    [Google Scholar]
  44. Reber A. J., Tanner M., Okinaga T., Woolums A. R., Williams S., Ensley D. T., Hurley D. J. 2006; Evaluation of multiple immune parameters after vaccination with modified live or killed bovine viral diarrhea virus vaccines. Comp Immunol Microbiol Infect Dis 29:61–77 [CrossRef]
    [Google Scholar]
  45. Ridpath J. F. 2005; Practical significance of heterogeneity among BVDV strains: impact of biotype and genotype on US control programs. Prev Vet Med 72:17–30 (discussion 215–219 [CrossRef]
    [Google Scholar]
  46. Ridpath J. F., Bolin S. R., Dubovi E. J. 1994; Segregation of bovine viral diarrhea virus into genotypes. Virology 205:66–74 [CrossRef]
    [Google Scholar]
  47. Sedegah M., Charoenvit Y., Minh L., Belmonte M., Majam V. F., Abot S., Ganeshan H., Kumar S., Bacon D. J. other authors 2004; Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 11:448–456 [CrossRef]
    [Google Scholar]
  48. Shimazaki T., Sekiguchi H., Nakamura S., Taguchi K., Inoue Y., Satoh M. 1998; Segregation of bovine viral diarrhea virus isolated in Japan into genotypes. J Vet Med Sci 60:579–583 [CrossRef]
    [Google Scholar]
  49. Shiver J. W., Fu T. M., Chen L., Casimiro D. R., Davies M. E., Evans R. K., Zhang Z. Q., Simon A. J., Trigona W. L. other authors 2002; Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331–335 [CrossRef]
    [Google Scholar]
  50. van Oirschot J. T., Bruschke C. J., van Rijn P. A. 1999; Vaccination of cattle against bovine viral diarrhoea. Vet Microbiol 64:169–183 [CrossRef]
    [Google Scholar]
  51. Vilcek S., Paton D. J., Durkovic B., Strojny L., Ibata G., Moussa A., Loitsch A., Rossmanith W., Vega S. other authors 2001; Bovine viral diarrhoea virus genotype 1 can be separated into at least eleven genetic groups. Arch Virol 146:99–115 [CrossRef]
    [Google Scholar]
  52. Vilcek S., Greiser-Wilke I., Durkovic B., Obritzhauser W., Deutz A., Kofer J. 2003; Genetic diversity of recent bovine viral diarrhoea viruses from the southeast of Austria (Styria). Vet Microbiol 91:285–291 [CrossRef]
    [Google Scholar]
  53. Vilcek S., Durkovic B., Kolesarova M., Paton D. J. 2005; Genetic diversity of BVDV: consequences for classification and molecular epidemiology. Prev Vet Med 72:31–35 (discussion 215–219 [CrossRef]
    [Google Scholar]
  54. Wakeley P. R., Turner J. L., Ibata G., King D. P., Sandvik T., Howard P., Drew T. W. 2004; Characterisation of a type 2 bovine viral diarrhoea virus isolated from cattle in the UK. Vet Microbiol 102:19–24 [CrossRef]
    [Google Scholar]
  55. Waldvogel A. S., Hediger-Weithaler B. M., Eicher R., Zakher A., Zarlenga D. S., Gasbarre L. C., Heussler V. T. 2000; Interferon- γ and interleukin-4 mRNA expression by peripheral blood mononuclear cells from pregnant and non-pregnant cattle seropositive for bovine viral diarrhea virus. Vet Immunol Immunopathol 77:201–212 [CrossRef]
    [Google Scholar]
  56. Webster D. P., Dunachie S., McConkey S., Poulton I., Moore A. C., Walther M., Laidlaw S. M., Peto T., Skinner M. A. other authors 2006; Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24:3026–3034 [CrossRef]
    [Google Scholar]
  57. Wolfmeyer A., Wolf G., Beer M., Strube W., Hehnen H. R., Schmeer N., Kaaden O. R. 1997; Genomic (5′UTR) and serological differences among German BVDV field isolates. Arch Virol 142:2049–2057 [CrossRef]
    [Google Scholar]
  58. Yu H., Babiuk L. A., van Drunen Littel-van den Hurk S. 2004; Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol 85:1533–1543 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83251-0
Loading
/content/journal/jgv/10.1099/vir.0.83251-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error